Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the 2-year results from Apellis' Phase 3 DERBY and OAKS Studies for EMPAVELI (pegcetacoplan) in Geographic Atrophy

Ticker(s): APLS

Who's the expert?

Institution: Duke

Assistant Professor of Ophthalmology, Ophthalmology, Vitreoretinal Diseases & Surgery at Duke.
Manages 500 patients with geographic atrophy.
Studies the biology, diagnosis and treatment of macular edema, and I am involved in basic laboratory science, ocular imaging analysis and clinical trials of new medications.

Interview Goal

This conversation will focus on the new data from DERBY/OAKS and the potential of EMPAVELI in treating Geographic Atrophy.

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.